Wall Street appears to be overly pessimistic about large pharmaceutical companies, and some of the stocks could rally 30% over the next year, according to a cover story in the June 28th edition of Barron's. Some of the best value lies in Merck & Co, Pfizer, Sanofi-Aventis, Novartis and Roche, according to the article in the weekly financial publication. Bristol-Myers Squibb, Eli Lilly and Astrazeneca do not look as attractive as some of their peers, the Barron's article said.

(6/28/2010)